Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ketorolac ophthalmic - AbbVie

Next Previous
X
Search
Drug Profile

Ketorolac ophthalmic - AbbVie

Alternative Names: ACULAR; ACULAR LS; ACULAR PF; ACUVAIL; Ketorolac tromethamine

Latest Information Update: 26 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer AbbVie
  • Class 2 ring heterocyclic compounds; Carboxylic acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrroles; Small molecules
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis; Postoperative inflammation; Postoperative pain

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Postoperative-inflammation in India (Ophthalmic, Drops)
  • 24 Jul 2009 The US FDA approves ACUVAIL™, a 45% ketorolac tromethamine ophthalmic solution, for the treatment of pain and inflammation following cataract surgery

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top